# Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

> **NCT07369986** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Women's Hospital School Of Medicine Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Endometrial Cancer
- Immunotherapy
- Mismatch Repair Deficiency

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab (QL1706)

## Key facts

- **NCT ID:** NCT07369986
- **Lead sponsor:** Women's Hospital School Of Medicine Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07369986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07369986, "Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT07369986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*